Uniqure Nv Quote - 0EE0

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

31.50

Bid

0.00

Offer

0.00

Volume

20,278

0.00 Day's Range 0.00

31.50 52 Week Range 31.50

Market Cap

1.507B

Previous Close

31.50

Open

Last Trade

100

17.4

(O)

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

14,811

Shares Outstanding

47,834,000

Dividend Yield

PE Ratio

-2.64

Earnings Per Share (EPS)

-6.45

Revenue

21.9M

Net Profit

-308.48M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.uniqure.com

Headquarters

Amsterdam, North Holland, Nld

Founded

Uniqure Nv is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker 0EE0. The last closing price for Uniqure Nv was US$31.50. Over the last year, Uniqure Nv shares have traded in a share price range of US$ 31.50 to US$ 31.50.

Uniqure Nv currently has 47,834,000 shares in issue. The market capitalisation of Uniqure Nv is US$1.51 billion. Uniqure Nv has a price to earnings ratio (PE ratio) of -2.64.

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease ~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing...

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy LEXINGTON, Mass. and AMSTERDAM, Nov. 21...

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress ~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions...

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V...

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease LEXINGTON, Mass. and AMSTERDAM, Sept. 23, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a...

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease LEXINGTON, Mass. and AMSTERDAM, Aug. 15, 2024 (GLOBE NEWSWIRE) -- uniQure...

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update ~ Announced RMAT designation for AMT-130 in Huntington’s disease and positive interim Phase I/II data...

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen ~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene...

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease ~ Achieved statistically significant...

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen ~ Proposed divestiture streamlines uniQure’s focus and represents an important milestone in its ongoing effort to...

Period	Open	High	Low	Avg. Daily Vol	VWAP
1	31.5	31.5	31.5	7937	31.5	DE
4	31.5	31.5	31.5	29025	31.5	DE
12	31.5	31.5	31.5	14811	31.5	DE
26	31.5	31.5	31.5	15703	31.5	DE
52	31.5	31.5	31.5	8630	31.5	DE
156	31.5	31.5	31.5	3191	31.5	DE
260	31.5	31.5	31.5	2018	31.5	DE

0EE0 - Frequently Asked Questions (FAQ)

What is the current Uniqure Nv share price?

The current share price of Uniqure Nv is US$ 31.50

How many Uniqure Nv shares are in issue?

Uniqure Nv has 47,834,000 shares in issue

What is the market cap of Uniqure Nv?

The market capitalisation of Uniqure Nv is USD 1.51B

What is the 1 year trading range for Uniqure Nv share price?

Uniqure Nv has traded in the range of US$ 31.50 to US$ 31.50 during the past year

What is the PE ratio of Uniqure Nv?

The price to earnings ratio of Uniqure Nv is -2.64

What is the cash to sales ratio of Uniqure Nv?

The cash to sales ratio of Uniqure Nv is 37.17

What is the reporting currency for Uniqure Nv?

Uniqure Nv reports financial results in USD

What is the latest annual turnover for Uniqure Nv?

The latest annual turnover of Uniqure Nv is USD 21.9M

What is the latest annual profit for Uniqure Nv?

The latest annual profit of Uniqure Nv is USD -308.48M

What is the registered address of Uniqure Nv?

The registered address for Uniqure Nv is PAASHEUVELWEG 25A, AMSTERDAM, NORTH HOLLAND, 1105 BP

What is the Uniqure Nv website address?

The website address for Uniqure Nv is www.uniqure.com

Which industry sector does Uniqure Nv operate in?

Uniqure Nv operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
TIRTiger Royalties And Investments Plc	0.15p (50.00%)	3.41M
BAYBay Capital Plc	5.50p (19.57%)	209.68k
MASTMast Energy Developments Plc	0.19p (18.75%)	20.09M
MHNMenhaden Resource Efficiency Plc	148.50p (18.33%)	1M
ZENZenith Energy Ltd.	2.50p (16.28%)	3.93M
TRYBTribe Technology Plc	0.115p (-79.09%)	24.27M
NMTNeometals Ltd	2.75p (-35.29%)	49.4k
SNGSynairgen Plc	2.46p (-34.31%)	4.31M
TM1Technology Minerals Plc	0.185p (-26.00%)	174.03M
AYMAnglesey Mining Plc	0.70p (-17.65%)	2.99M
NTVONativo Resources Plc	0.002p (5.26%)	971.94M
TRPTower Resources Plc	0.035p (9.38%)	620.03M
LLOYLloyds Banking Group Plc	54.16p (-0.26%)	341.48M
ORCPOracle Power Plc	0.0255p (-1.92%)	192.93M
TM1Technology Minerals Plc	0.185p (-26.00%)	174.03M